中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

19 records (took 0.02 seconds)

    PREDICTION OF POSTPARTUM HELLP SYNDROME, POSTPARTUM ECLAMPSIA OR POSTPARTUM PREECLAMPSIA
    11.
    发明申请
    PREDICTION OF POSTPARTUM HELLP SYNDROME, POSTPARTUM ECLAMPSIA OR POSTPARTUM PREECLAMPSIA 审中-公开
    前列腺癌综合征，前列腺癌或前列腺癌的预测

    公开(公告)号：US20160327564A1

    公开(公告)日：2016-11-10

    申请号：US15216980

    申请日：2016-07-22

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Martin Hund ,  Thomas Dieterle ,  Olav Lapaire

    IPC: G01N33/68

    CPC classification number: G01N33/689 ,  G01N33/6863 ,  G01N2333/515 ,  G01N2333/705 ,  G01N2333/91205 ,  G01N2800/368 ,  G01N2800/50

    Abstract: The present invention is directed to a method for predicting the risk of a female subject to develop postpartum HELLP syndrome, postpartum preeclampsia, or postpartum eclampsia. The method is based on the determination of the levels of i) sFlt-1 and PlGF, or ii) Endoglin and PlGF in a first sample obtained from said subject before delivery of baby, and a second sample of from said subject obtained after delivery of baby. Moreover, encompassed by the invention are devices and kits for carrying out the method of the present invention.

    Abstract translation: 本发明涉及一种预测女性受试者产生产后HELLP综合征，产后先兆子痫或产后子痫风险的方法。 该方法是基于i）sFlt-1和PlGF的水平的确定，或ii）在分娩前从所述受试者获得的第一样品中的内皮糖蛋白和PlGF，以及在分娩后获得的来自所述受试者的第二个样品 宝宝。 此外，本发明包括用于实施本发明的方法的装置和套件。

    MARKER FOR STATIN TREATMENT STRATIFICATION IN HEART FAILURE
    14.
    发明申请
    MARKER FOR STATIN TREATMENT STRATIFICATION IN HEART FAILURE 审中-公开
    心脏失败症状治疗的标记标记

    公开(公告)号：US20160169911A1

    公开(公告)日：2016-06-16

    申请号：US15054255

    申请日：2016-02-26

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Dirk Block ,  Hanspeter Brunner ,  Thomas Dieterle ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg ,  Andre Ziegler

    IPC: G01N33/68 ,  G01N33/62

    CPC classification number: G01N33/6893 ,  A61K31/40 ,  G01N33/62 ,  G01N33/6869 ,  G01N33/6872 ,  G01N2333/47 ,  G01N2333/475 ,  G01N2333/495 ,  G01N2333/5412 ,  G01N2800/325 ,  G01N2800/52

    Abstract: The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.

    Abstract translation: 本发明涉及鉴定患有心力衰竭的患者可能对包含他汀类药物的疗法有反应的方法。 该方法基于测量选自GDF-15（生长分化因子15），尿素，SHBG（性激素结合球蛋白），尿酸，PLGF（胎盘生长因子），IL-6（ 白细胞介素-6），转铁蛋白，心肌肌钙蛋白，sFlt-1（可溶性fms样酪氨酸激酶-1），前白蛋白，铁蛋白，骨桥蛋白，sST2（可溶性ST2）和hsCRP（高灵敏度C反应蛋白） 从病人。 进一步设想的是预测患者遭受死亡或住院的风险的方法，其中所述患者具有心力衰竭并经历包含他汀类药物的治疗。 该方法还基于至少一种上述标记的水平的测量。

    Marker for statin treatment stratification in heart failure
    16.
    发明授权
    Marker for statin treatment stratification in heart failure 有权

    公开(公告)号：US11460474B2

    公开(公告)日：2022-10-04

    申请号：US16257770

    申请日：2019-01-25

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Dirk Block ,  Hanspeter Brunner ,  Thomas Dieterle ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg ,  Andre Ziegler

    IPC: G01N33/543 ,  G01N33/68 ,  A61K31/40 ,  G01N33/62

    Abstract: The present disclosure is directed to a method of identifying a patient having heart failure as likely to respond to a therapy with a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein the patient has heart failure and undergoes a therapy with a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.

Patent Agency Ranking